Alban C.’s Post

Exciting to see infinitas capital and Opportuna featured in Bloomberg as part of the growing conversation around family offices and the secondary market. With liquidity tightening and investor demand building, Opportuna is seizing the potential of venture secondaries, offering an avenue to unlock liquidity and realize solid gains within a shorter timeframe. To learn more about @Opportuna and our strategy, reach out to Alban C. or Christopher L.R. Chuffart

Our CEO Robin Lauber highlights that "the timing seems right" to invest in secondary markets. Read the full Bloomberg News article here: https://lnkd.in/gmwXN_En With traditional liquidity channels tightening, secondary sales offer family offices access to high growth, mature private companies at attractive valuations. In this context, we launched Opportuna, our new venture secondaries vehicle. Reasons why we are drawn to secondaries: * Unlocking liquidity in constrained markets * Gaining access to established companies with proven growth * Continuation funds provide stability and upside potential #privateequity #venturecapital #secondarymarket #familyoffice #venturesecondaries

Opportuna and infinitas capital highlighted in Bloomberg's latest article on the evolving secondaries market, which speaks to the demand for innovative approaches to liquidity in private markets. We think there is 15-20y of backlog in both the US and Europe. 👉 For those interested in deeper insights and the trends shaping private markets, I share exclusive updates through my Beehiiv newsletter. Join our community here: https://lnkd.in/eY8KuN9N 👉 For those interested in selling a stake or simply knowing more about the asset class, you can contact us here: https://lnkd.in/eaSwVBXW #VentureSecondaries #FamilyOffices #BloombergFeature #Newsletter #PrivateMarkets

With median discounts since the last primary funding round exceeding 50% since 2023, secondaries are a tempting target for family offices. Secondary investing is a different skillset from primary investment. All because a company's stock price has fallen, does not mean it is "on sale." Success for family offices will depend on understanding the reasons for the drop in price and whether even the discounted price reflects actual fair market value. Also, unless the company is raising new funds in connection with the secondary, the sufficiency of the company's capitalization is critical. A good company with insufficient cash is not a bargain, even at a discounted price. https://lnkd.in/ebA8esYX

As Ben Stupples and Annie Massa of Bloomberg News highlighted this week, #familyoffices are infusing new capital into the booming secondaries market. Family offices’ allocations to #secondaries are surging, bringing new liquidity to private equity firms facing a liquidity crunch. However, Tangible has seen that family offices aren’t just buying secondaries — they’re also transforming the market as sellers. Many family offices and high-net-worth investors are currently seeking liquidity across earlier vintages. Historically, the secondary market was inaccessible for all but the largest institutional investors, but that’s changed. Tangible’s platform offers family offices and other LPs a way to get early exits for private market stakes between $500K and $100M+. From pricing analytics to digital auctions, we’re committed to making the secondary market more accessible. To schedule a demo or learn more, reach out to Khalil Hibri in Europe or Jeff Pinksa in the US. https://lnkd.in/gmwXN_En

🌍 The Family Office landscape is evolving, and we're seeing a major trend emerging: Family Offices are flocking to the $140 billion market for secondary sales. 📈 According to Bloomberg, more and more Family Offices are exploring secondary transactions as a strategy to increase liquidity and diversify their holdings in private investments. This shift reflects a growing sophistication among Family Offices in navigating the alternative investment landscape—something we at Ledgex have been prepared for since day one. Our platform is designed to support these evolving strategies by simplifying complex data management and providing a clear view of all investment types, including secondary transactions. As Family Offices continue to expand their focus on alternative investments, tools that can handle this complexity are no longer just a luxury—they are essential. If you’re curious about how the secondary sales market is impacting Family Offices and how Ledgex can help navigate these opportunities, check out the full article here: https://lnkd.in/ePB2x4JC #FamilyOffices #AlternativeInvestments #SecondaryMarket #Ledgex #WealthManagement #InnovationInFinance #PrivateWealth Nicole Eberhardt, Peter Cunha, Wendy McCoy, Christopher McCoy, Brian Nickerson

Brandon Capital, a leading life sciences VC firm in Australia, has another AUD $270 million (~ $180 million) to support 15 to 20 startups in drug development, health tech and medical devices. While the US-to-Europe life sciences investing axis is well established at this point, with many biotech VCs supporting new drug developers from Boston to Basel and elsewhere across the pond, the path between Australasia and Europe is less trodden, Brandon Capital partner Jonathan Tobin said in an interview with Endpoints News. #lifesciences #biotechfunding #biotechstartups #australia #australasia #venturecapital

On today’s episode of IR Update, Amanda Munhoz interviews Matthew Mills, CEO of Med-X, Inc. Matthew discusses Med-X’s founding, the importance of green solutions, and the company’s successful journey in pest control. He also details how the journey of crowdfunding for a direct NASDAQ listing is a strategic move to attract investment and expand operations. Click here for the full interview: https://lnkd.in/dgxC8a-h Follow the MZ Insights page to learn more about direct listing, IPOs, and investor relations. We publish articles, studies, and interviews with IROs from all industries and regions. #InvestorRelations #IPO #MedEX #IRInsights #IRUpdate

Outstanding program and panel discussion last night hosted by Ryan Dolan and CFGI on the Capital Markets Landscape within the Boston Life Sciences ecosystem along with insights from former Chairman of the SEC, Jay Clayton. The discussion included a retrospective on companies prepared for IPO's and a look forward at what positive movement in interest rates could mean for increased activity in 2025. The biotech community was out in full force and it was great running into faces new and old. #LifeSciences #CapitalMarkets #MMALifeSciencesPractice

Catch up on the latest transactions with our Diagnostics and Tools BlueBook, designed to provide valuable perspectives for industry leaders and private equity professionals. Discover a monthly executive review that captures the essence of valuation trends, M&A developments, and transactions. Key highlights from the October 2024 edition include: 📌Nusano closed a $115MM Series A Financing, led by Verily Life Sciences, Section 32, Wasatch Venture Partners, and American Cancer Society’s BrightEdge 📌Vizgen closed a $150.3MM Series A Financing, led by Arch Venture Partners, Tao Capital Partners, and Northpond Ventures 📌Cytovale closed a $100MM Series A Financing, led by Breakout Ventures, Canada Pension Plan Investment Board, Sands Capital Management, Breakout Ventures, and Global Health Investment Corporation Want to read more? Download using the link below: https://hubs.li/Q02ZCFM90 #InvestmentBanking #MergersAndAcquisitions #LifeSciences #PrivateEquity